154 related articles for article (PubMed ID: 33991247)
1. Prognostic relevance of Ki67 expression in primary male breast cancer: determination of cut-off points by different evaluation methods and statistical examinations.
Erices-Leclercq M; Lubig S; Förster F; Förster R; Baldus S; Rudlowski C; Schröder L
J Cancer Res Clin Oncol; 2022 Feb; 148(2):441-447. PubMed ID: 33991247
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study.
Healey MA; Hirko KA; Beck AH; Collins LC; Schnitt SJ; Eliassen AH; Holmes MD; Tamimi RM; Hazra A
Breast Cancer Res Treat; 2017 Nov; 166(2):613-622. PubMed ID: 28791482
[TBL] [Abstract][Full Text] [Related]
3. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation.
Carbognin L; Sperduti I; Fabi A; Dieci MV; Kadrija D; Griguolo G; Pilotto S; Guarneri V; Zampiva I; Brunelli M; Orvieto E; Nortilli R; Fiorio E; Parolin V; Manfrin E; Caliò A; Nisticò C; Pellini F; Scarpa A; Pollini GP; Conte P; Tortora G; Bria E
Breast; 2017 Oct; 35():21-26. PubMed ID: 28628772
[TBL] [Abstract][Full Text] [Related]
5. Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.
Muftah AA; Aleskandarany MA; Al-Kaabi MM; Sonbul SN; Diez-Rodriguez M; Nolan CC; Caldas C; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2017 Jul; 164(2):341-348. PubMed ID: 28478613
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer.
Zenzola V; Cabezas-Quintario MA; Arguelles M; Pérez-Fernández E; Izarzugaza Y; Correa A; García-Foncillas J
Clin Transl Oncol; 2018 Nov; 20(11):1448-1454. PubMed ID: 29671222
[TBL] [Abstract][Full Text] [Related]
7. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up.
Bustreo S; Osella-Abate S; Cassoni P; Donadio M; Airoldi M; Pedani F; Papotti M; Sapino A; Castellano I
Breast Cancer Res Treat; 2016 Jun; 157(2):363-371. PubMed ID: 27155668
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study.
Tashima R; Nishimura R; Osako T; Nishiyama Y; Okumura Y; Nakano M; Fujisue M; Toyozumi Y; Arima N
PLoS One; 2015; 10(7):e0119565. PubMed ID: 26177501
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays.
Knutsvik G; Stefansson IM; Aziz S; Arnes J; Eide J; Collett K; Akslen LA
PLoS One; 2014; 9(11):e112121. PubMed ID: 25375149
[TBL] [Abstract][Full Text] [Related]
10. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?
Ahlin C; Aaltonen K; Amini RM; Nevanlinna H; Fjällskog ML; Blomqvist C
Histopathology; 2007 Oct; 51(4):491-8. PubMed ID: 17711446
[TBL] [Abstract][Full Text] [Related]
11. A Prognostic Analysis of Male Breast Cancer (MBC) Compared with Post-Menopausal Female Breast Cancer (FBC).
Yu XF; Yang HJ; Yu Y; Zou DH; Miao LL
PLoS One; 2015; 10(8):e0136670. PubMed ID: 26313461
[TBL] [Abstract][Full Text] [Related]
12. Machine Learning Approach for the Determination of the Best Cut-Off Points for Ki67 Proliferation Index in Adjuvant and Neo-Adjuvant Therapy Breast Cancer Patients.
Khosravi S; Khayyamfar A; Karimi J; Tutuni M; Negahi A; Akbari ME; Nafissi N
Clin Breast Cancer; 2023 Jul; 23(5):519-526. PubMed ID: 37156698
[TBL] [Abstract][Full Text] [Related]
13. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
Clin Breast Cancer; 2017 Aug; 17(5):356-366. PubMed ID: 28576631
[TBL] [Abstract][Full Text] [Related]
14. Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
Robertson S; Acs B; Lippert M; Hartman J
Breast Cancer Res Treat; 2020 Aug; 183(1):161-175. PubMed ID: 32572716
[TBL] [Abstract][Full Text] [Related]
15. Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis.
Gallardo A; Garcia-Valdecasas B; Murata P; Teran R; Lopez L; Barnadas A; Lerma E
Breast Cancer Res Treat; 2018 Jan; 167(1):31-37. PubMed ID: 28865009
[TBL] [Abstract][Full Text] [Related]
16. Male breast cancer: Looking for better prognostic subgroups.
Abreu MH; Afonso N; Abreu PH; Menezes F; Lopes P; Henrique R; Pereira D; Lopes C
Breast; 2016 Apr; 26():18-24. PubMed ID: 27017238
[TBL] [Abstract][Full Text] [Related]
17. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
Denkert C; Loibl S; Müller BM; Eidtmann H; Schmitt WD; Eiermann W; Gerber B; Tesch H; Hilfrich J; Huober J; Fehm T; Barinoff J; Jackisch C; Prinzler J; Rüdiger T; Erbstösser E; Blohmer JU; Budczies J; Mehta KM; von Minckwitz G
Ann Oncol; 2013 Nov; 24(11):2786-93. PubMed ID: 23970015
[TBL] [Abstract][Full Text] [Related]
18. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
[TBL] [Abstract][Full Text] [Related]
19. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
20. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.
Fasching PA; Heusinger K; Haeberle L; Niklos M; Hein A; Bayer CM; Rauh C; Schulz-Wendtland R; Bani MR; Schrauder M; Kahmann L; Lux MP; Strehl JD; Hartmann A; Dimmler A; Beckmann MW; Wachter DL
BMC Cancer; 2011 Nov; 11():486. PubMed ID: 22081974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
